References
- Cheng, Y. and Prusoff, W.H., 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical pharmacology, 22 (23), 3099–3108.
- Correll, C.U., et al., 2015. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. The American journal of psychiatry, 172 (9), 870–880.
- Fleischhacker, W.W., et al., 2017. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia a randomized, double-blind, placebo-controlled study. International journal of neuropsychopharmacology., 20 (1), 11–21.
- Garnock-Jones, K.P., 2016. Brexpiprazole: a review in schizophrenia. CNS drugs, 30 (4), 335–342. http://dx.doi.org/10.1007/s40263-016-0325-8.
- Ishigooka, J., Shuichi Iwashita, S., and Tadori, Y., 2018a. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry and clinical neurosciences, 72 (9), 692–700.
- Ishigooka, J., et al., 2018b. Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. Journal of clinical pharmacology, 58 (1), 74–80.
- Maeda, K., et al., 2014a. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. Journal of pharmacology and experimental therapeutics, 350 (3), 589–604.
- Maeda, K., et al., 2014b. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. The journal of pharmacology and experimental therapeutics, 350 (3), 605–614.
- Sasabe, H., et al., 2021. In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. Xenobiotica.
- Shimada, T., et al., 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians1. Journal of pharmacology and experimental therapeutics, 270 (1), 414–423.
- Tadori, Y., et al., 2005. Aripiprazole’s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European journal of pharmacology, 515 (1-3), 10–19. http://dx.doi.org/10.1016/.j.ejphar.2005.02.051
- Thakkar, D. and Kate, A.S., 2019. In silico, in vitro and in vivo metabolite identification of brexpiprazole using ultra-high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid communications in mass spectrometry : RCM, 33 (11), 1024–1035.